Table 4.
The description of the vitamin D exposures applied within the studies and mental health outcomes assessed within the studies of multiple sclerosis (MS) patients included to the systematic review.
| Ref. | Vitamin D Measure | Assessed Vitamin D Supplementation | Mental Health Outcome | Psychological Measure |
|---|---|---|---|---|
| [35] | 25(OH)D blood level | 1250 µg/5 days for 3 months vs. placebo | Quality of life | Multiple sclerosis quality of life (MSQOL-54)—Persian version |
| [36] | 25(OH)D blood level | 175 µg/day for 4 weeks followed by 350 µg/day for 44 weeks vs. placebo | (1) Depressive symptoms (2) Fatigue |
(1) Depression subscale of the Hospital Anxiety and Depression Scale (HADS) (2) Dutch version of the Fatigue Severity Scale (FSS) |
| [37] | 25(OH)D blood level | 250 µg/day for 12 months | Depressive symptoms | Beck’s depression inventory (BDI) |
| [38] | 25(OH)D blood level | In patients with serum 25(OH)D <30 ng/mL–1250 µg/week for 8 weeks (to reach a minimum serum 25(OH)D level of 30 ng/mL) followed by 37.5–50 µg/day In patients with serum 25(OH)D of 20–30 ng/mL–37.5–50 µg/days |
(1) Quality of life (2) Fatigue |
(1) Multiple sclerosis-related quality of life inventory (MSQOLI) (2) Fatigue Severity Scale (FSS) |
| [39] | Taking vitamin D supplement | Declared vitamin D supplementation taken vs. not taken in the follow up of 2.5 years | Depression | Patient Health Questionnaire-2 (PHQ-2) Patient, Health Questionniare-9 (PHQ-9) |
| [40] | Taking vitamin D supplement | Declared vitamin D supplementation taken vs. not taken in the follow up of 2.5 years | Quality of life | Multiple sclerosis quality of life (MSQOL-54) |